STOCK TITAN
  1. Home
  2. News
  3. PYPD

PolyPid Ltd. Ordinary Shares - PYPD STOCK NEWS

Welcome to our dedicated page for PolyPid Ltd. Ordinary Shares news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on PolyPid Ltd. Ordinary Shares stock.

PolyPid Ltd. (Nasdaq: PYPD) is a cutting-edge biopharmaceutical company focused on enhancing surgical outcomes through its innovative drug delivery technology, PLEX™ (Polymer-Lipid Encapsulation matriX). This proprietary technology allows for the precise, prolonged release of drugs directly at the target site, optimizing therapeutic performance and clinical outcomes. PolyPid specializes in the development and manufacturing of products that address unmet medical needs, particularly in the prevention of surgical site infections (SSIs) and treatment of solid tumors.

The company's lead product candidate, D-PLEX100, is designed to provide localized, controlled anti-bacterial activity at surgical sites to prevent SSIs. It is currently undergoing a Phase 3 clinical trial, known as SHIELD II, aimed at preventing infections in patients undergoing open abdominal colorectal surgery. D-PLEX100 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address significant medical needs.

PolyPid's product pipeline also includes OncoPLEX, intended for the treatment of solid tumors, beginning with glioblastoma. This product is currently in preclinical stages, showing promising potential in oncology. Additionally, the company's proprietary technology, PLEX™, can encapsulate various drugs, enabling targeted and localized delivery over extended periods, ranging from several days to months.

In terms of recent achievements, PolyPid has successfully enrolled and randomized over 200 patients in its SHIELD II trial, with top-line results expected in the second half of 2024. Moreover, the company recently closed a $16 million private placement financing, which will support ongoing clinical development efforts and extend its cash runway beyond the anticipated interim analysis of the SHIELD II trial.

For more detailed information, visit PolyPid's official website or follow the company on Twitter and LinkedIn.

News

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) will report its fourth quarter and full-year 2023 financial results and operational highlights on February 14, 2024. The Company aims to improve surgical outcomes and will host a conference call and webcast to discuss the results and provide an update on business operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
conferences earnings
-
News

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) announced a private placement financing (the “PIPE”) for $16.2 million in gross proceeds. The financing is led by leading U.S. life sciences-focused investors, DAFNA Capital Management and Rosalind Advisors. The investors have agreed to purchase 3,371,312 of the Company’s ordinary shares at a purchase price of $4.81 per share, with additional warrants to purchase up to 3,371,312 ordinary shares at an exercise price of $5.50 per share. The PIPE is expected to close on January 9, 2024, and the net proceeds will be used for the ongoing SHIELD II phase 3 clinical trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.36%
Tags
none
-
News

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) provided a corporate update and reported financial results for the three and nine months ended September 30, 2023. The update highlights the progress of the SHIELD II Phase 3 trial for D-PLEX100, successful completion of manufacturing milestones, and financial results. The company expects to have approximately 40 centers open by the end of 2023, with top-line results from the SHIELD II trial expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
earnings
News

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A., to its Board of Directors following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is currently the CEO of MediCane Health, a global medical cannabis company, and previously held senior positions at aMOON and Sanofi. Dr. Tweezer-Zaks will bring her vast expertise to help PolyPid approach critical clinical and regulatory milestones, including the potential commercialization of their late-stage product candidate, D-PLEX100, for the prevention of surgical site infections (SSIs).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
management
-
News

PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) will report its Q3 2023 financial results and operational highlights on November 8, 2023. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Rhea-AI Summary
PolyPid regains compliance with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
none
News

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

Rhea-AI Summary
PolyPid to present SHIELD I Phase 3 clinical data for D-PLEX100 at American College of Surgeons Clinical Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
none
-
News

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

Rhea-AI Summary
PolyPid announces positive preclinical results demonstrating the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
clinical trial
-
News

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Rhea-AI Summary
PolyPid to present at Cantor Global Healthcare Conference on September 28, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.24%
Tags
conferences
News

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

Rhea-AI Summary
PolyPid successfully completes audit of manufacturing facility for D-PLEX100, bringing them closer to global commercialization
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.7%
Tags
none

FAQ

What is the current stock price of PolyPid Ltd. Ordinary Shares (PYPD)?

The current stock price of PolyPid Ltd. Ordinary Shares (PYPD) is $3.22 as of December 20, 2024.

What is the market cap of PolyPid Ltd. Ordinary Shares (PYPD)?

The market cap of PolyPid Ltd. Ordinary Shares (PYPD) is approximately 23.8M.

What is PolyPid Ltd. known for?

PolyPid Ltd. is known for its innovative drug delivery technology, PLEX™, which enables prolonged, localized drug release to enhance surgical outcomes and treat infections and tumors.

What is D-PLEX100?

D-PLEX100 is PolyPid's lead product candidate designed to prevent surgical site infections by providing localized, controlled anti-bacterial activity directly at surgical sites.

What clinical trials is PolyPid currently conducting?

PolyPid is currently conducting the SHIELD II Phase 3 trial for D-PLEX100, focusing on preventing surgical site infections in patients undergoing open abdominal colorectal surgery.

What is the PLEX™ technology?

PLEX™ (Polymer-Lipid Encapsulation matriX) is PolyPid's proprietary technology that allows for the precise, prolonged release of drugs at target sites, optimizing therapeutic performance.

What are PolyPid’s recent financial achievements?

PolyPid recently closed a $16 million private placement financing to support its clinical development efforts and has potential access to an additional $19 million through warrant exercises.

What recognition has D-PLEX100 received?

D-PLEX100 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for preventing surgical site infections in patients undergoing elective colorectal surgery.

What other products are in PolyPid’s pipeline?

In addition to D-PLEX100, PolyPid is developing OncoPLEX for the treatment of solid tumors, currently in the preclinical stage, showing potential in oncology.

Where can I find more information about PolyPid?

For more information, visit PolyPid's official website at www.polypid.com, or follow the company on Twitter and LinkedIn.

What is the target market for PolyPid's products?

PolyPid's products target medical needs in preventing surgical site infections and treating solid tumors, with a focus on improving surgical outcomes through extended drug delivery.

Who are the key investors in PolyPid?

PolyPid's recent financing included participation from leading U.S. life sciences-focused investors, such as DAFNA Capital Management and Rosalind Advisors.

Stock PYPD logo
PolyPid Ltd. Ordinary Shares

Nasdaq:PYPD

PYPD Rankings

#5230 Ranked by Market Cap
N/A Ranked by Dividends

PYPD Stock Data

23.81M
4.66M
24.24%
36.75%
0.23%
Biotechnology
Healthcare
Link
United States of America
Petah Tikva